1. ArtavanisTsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284:770776
2. Bender M, Gao H, Capen A, Clay J, Hipskind P, Reel J, Zamek-Gliszczynski M, Manro J, Benhadji K, Patel B (2013) Abstract 1131: novel inhibitor of notch signaling for the treatment of cancer. Proc: AACR 104th Annual Meeting 73(8):1131
3. Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel B, Yuen E, Benhadji K, Rodon J (2018) First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer. Ann Onc 29(9):1911–1917
4. Yuen E, Patel B, Smith C, Posada M, Bell R, Ohnmacht U, Massard C, Rodon J, Benhadji K (2016) Abstract CT048: population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in the first-in-man study. Cancer Res 76(14):CT048
5. International Conference on Harmonization (2015) E14 Implementation Working Group—ICH E14 Guideline: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs—Questions & Answers (R3).
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Q_As_R3__Step4.pdf
. Accessed 1 Aug 2017